

Impact of Dupilumab on the Ability to Enjoy Life in Patients With Moderate-to-Severe Atopic Dermatitis

Alexa B. Kimball¹, Min Yang², Bruno Martins², Ashley Holub², Jingdong Chao³, Gaëlle Bégo-Le-Bagousse⁴, Kerry Noonan⁵, Zhixiao Wang³

¹Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA; ²Analysis Group, Boston, MA, USA; ³Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA; ⁴Sanofi, Gentilly, France; ⁵Sanofi, Cambridge, MA, USA

Key takeaway

Patients reported a substantial burden on their ability to enjoy daily life due to uncontrolled moderate-to-severe AD before dupilumab. Following dupilumab treatment, many patients reported a substantial improvement in their ability to live and enjoy daily life

Objective

To analyze the impact of moderate-to-severe AD and the effect of dupilumab, a biologic treatment for AD, on patients' ability to enjoy life

Background

- AD is a chronic systemic disease associated with significant clinical and psychological burden, such as limitations in lifestyle choices, impaired activities, and avoidance of social interaction¹

Methods

- Adult patients with moderate-to-severe AD enrolled in RELIEVE-AD (a prospective, long-term survey study) who completed the Year 6 survey were invited to participate in qualitative one-on-one interviews lasting up to 60 minutes
- The semi-structured interview consisted of open-ended questions focusing on different domains of life (i.e. impacts on relationships and social life, day-to-day aspects of life such as clothing and diet, and leisure) before and after initiating dupilumab
- Content analysis using ATLAS.ti (version 24) was conducted on the qualitative data obtained from the interviews
- Responses were counted if patients affirmed having the experience


Results

Demographics and medical history

	Interview participants n = 50
Female, n (%)	31 (62.0)
Age at dupilumab initiation, mean (SD), years	45.4 (14.8)
Race, n (%)	
White or Caucasian	36 (72.0)
Age at AD diagnosis, mean (SD), years	26.3 (23.7)
Median (IQR)	16.0 (5.0–51.0)
Range	(1.0–67.0)
Medical history, n (%)	
Non-seasonal allergies ^a	18 (36.0)
Asthma	16 (32.0)
Type 2 comorbidities ^b	27 (54.0)
Hypertension	16 (32.0)
Anxiety	11 (22.0)
Depression	8 (16.0)
Obesity	9 (18.0)
Sleep disorders	4 (8.0)
Anemia	7 (14.0)
Disease control based on ADCT total score ^c , n (%)	
Uncontrolled (total score ≥7) at baseline	47 (94.0)
Uncontrolled (total score ≥7) at Year 6	4 (8.0)


^aAllergic rhinitis or runny nose, allergic conjunctivitis or pink eye, food allergies, allergic urticaria or hives, or other allergies. ^bAsthma or non-seasonal allergies. ^cAssessed using the ADCT, with a score <7 on a scale of 0–24 indicating controlled disease.

Negative impact of AD on family life, personal life, and relationships before dupilumab^a




^aResults presented for responses ≥10%.

Improvement in AD-related impact on family life, personal life, and relationships after receiving dupilumab treatment^a




^aResults presented for responses ≥6%.

Negative impact of AD on leisure, vacations, clothing, and diet before dupilumab^a



^aResults presented for responses ≥10%.

Improvement in AD-related impact on leisure, vacations, clothing, and diet after receiving dupilumab treatment^a



^aResults presented for responses ≥10%.

Selected patient quotes about AD-related impact on the ability to enjoy life before and after dupilumab treatment

Before dupilumab

[ID AL00ZUQE] "Before, I avoided all contact because I was not comfortable in my skin. It would just be blistering and oozing. It was just horrible."

[ID AL010DAV] "My chest, my back, all over, and what was funny was that I would react differently to different foods, sometimes I would have something and I will have like all these symptoms on my lower leg and feet."

[ID AL00ZGMK] "There was no sports, so I could not do sports. No sleepovers because of the routines or the non-sleeping or the embarrassing moments. There were no sleepovers when I was little. Some of our family did lots of camping outings, beach outings. I can never be a part of those. [...] There were no pets I could have. I could not go play on the grass. Anything that had high allergens I could not be around; I could not do so. I could not participate in a lot of those events. I never really thought of it when I was little. It was just the way it was."

After dupilumab

[ID AL00ZGMK] "Now that I do not have it, you cannot stop me. My husband yells at me because I am a go-go-go person now. I always want to be out of the house. I always want to be doing something. I always want to be around people. I want to be involved in everything."

[ID AL010FCG] "Just changed completely. 180-degree change. I can play with the kids, no issues. Sleeping, intimacy is completely different. 180-degree difference."

[ID AL010NN6] "I do not have to worry about having the flare-ups. It is the same answer basically. I can take any vacation at any time, and I do not have to worry about any type of flare-ups at all."

AD, atopic dermatitis; ADCT, Atopic Dermatitis Control Tool; IQR, interquartile range; SD, standard deviation.

Reference: 1. Silverberg JJ, et al. Ann Allergy Asthma Immunol.2018; 121:340–7.

Acknowledgments and funding sources: Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. Medical writing/editorial assistance was provided by Irina Milanova, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice guidelines.

Disclosures: Kimball AB: AbbVie, Eli Lilly, Incyte, Novartis, Pfizer, Regeneron Pharmaceuticals Inc. – grants; AbbVie, Eli Lilly, Novartis, Pfizer, Sanofi, Target RWE – consulting fees; Target RWE – advisory board; Almirall – board of directors. Yang M, Martins B, Holub A: Analysis Group (a company that received research funds from Sanofi-Regeneron Pharmaceuticals Inc. during the conduct of the study) – employees. Chao J, Wang Z: Regeneron Pharmaceuticals Inc. – employees and shareholders. Bégo-Le-Bagousse G, Noonan K: Sanofi – employees, may hold stock and/or stock options in the company.